SYRE | Spyre Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	29.51 - 30.40
52 Week Range	8.43 - 47.97
Beta	2.51
Implied Volatility	93.16%
IV Rank	71.20%
Day's Volume	98,023
Average Volume	611,138
Shares Outstanding	50,919,700
Market Cap	1,536,501,948
Sector	Healthcare
Industry	Biotechnology
IPO Date	2016-04-07

Valuation
Profitability
Growth
Health
P/E Ratio	2.77
Forward P/E Ratio	N/A
EPS	10.89
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	50
Country	USA
Website	SYRE

Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

*Chart delayed

Analyzing fundamentals for SYRE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SYRE Fundamentals page.

Watching at SYRE technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on SYRE Technicals page.